[go: up one dir, main page]

CL2019003903A1 - Uso de edaravona en el tratamiento oral de trastornos neurodegenerativos medidos por estrés oxidativo. - Google Patents

Uso de edaravona en el tratamiento oral de trastornos neurodegenerativos medidos por estrés oxidativo.

Info

Publication number
CL2019003903A1
CL2019003903A1 CL2019003903A CL2019003903A CL2019003903A1 CL 2019003903 A1 CL2019003903 A1 CL 2019003903A1 CL 2019003903 A CL2019003903 A CL 2019003903A CL 2019003903 A CL2019003903 A CL 2019003903A CL 2019003903 A1 CL2019003903 A1 CL 2019003903A1
Authority
CL
Chile
Prior art keywords
oxidative stress
edaravone
neurodegenerative disorders
oral treatment
amylophedad
Prior art date
Application number
CL2019003903A
Other languages
English (en)
Inventor
Der Geest Ronald Van
Sytske Hyke Moolenaar
Original Assignee
Treeway Tw001 Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2018/051097 external-priority patent/WO2018134243A1/en
Application filed by Treeway Tw001 Bv filed Critical Treeway Tw001 Bv
Publication of CL2019003903A1 publication Critical patent/CL2019003903A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE AL USO DE UNA SOLUCIÓN ACUOSA LÍQUIDA DE EDARAVONA EN EL TRATAMIENTO DE UN TRASTORNO NEURODEGENERATIVO MEDIADO POR ESTRÉS OXIDATIVO EN UN PACIENTE HUMANO, COMPRENDIENDO DICHO TRATAMIENTO LA ADMINISTRACIÓN ORAL AL MENOS UNA VEZ AL DÍA DE LA SOLUCIÓN LÍQUIDA DE EDARAVONA AL PACIENTE HUMANO, PARA PROPORCIONAR UNA DOSIS DIARIA DE 40-120 MG DE EDARAVONA DURANTE UN PERÍODO ININTERRUMPIDO DE AL MENOS 10 DÍAS. LOS EJEMPLOS DE TRASTORNOS NEURODEGENERATIVOS MEDIADOS POR EL ESTRÉS OXIDATIVO QUE PUEDEN TRATARSE DE ESTA MANERA INCLUYEN ESCLEROSIS LATERAL AMIOTRÓFICA (ELA), ESCLEROSIS MÚLTIPLE (EM), ANGIOPATÍA AMILOIDE CEREBRAL (AAC), ENFERMEDAD DE ALZHEIMER Y ENFERMEDAD DE PARKINSON.
CL2019003903A 2017-07-06 2019-12-30 Uso de edaravona en el tratamiento oral de trastornos neurodegenerativos medidos por estrés oxidativo. CL2019003903A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17180087 2017-07-06
PCT/EP2018/051097 WO2018134243A1 (en) 2017-01-17 2018-01-17 Treatment comprising oral or gastric administration of edaravone
EP18157678 2018-02-20

Publications (1)

Publication Number Publication Date
CL2019003903A1 true CL2019003903A1 (es) 2020-07-31

Family

ID=64949757

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003903A CL2019003903A1 (es) 2017-07-06 2019-12-30 Uso de edaravona en el tratamiento oral de trastornos neurodegenerativos medidos por estrés oxidativo.

Country Status (11)

Country Link
US (1) US12370139B2 (es)
EP (1) EP3648760B1 (es)
JP (1) JP7277005B2 (es)
KR (1) KR20200024868A (es)
CN (1) CN110996944A (es)
AU (1) AU2018298431B2 (es)
BR (1) BR112020000173A2 (es)
CA (1) CA3069048A1 (es)
CL (1) CL2019003903A1 (es)
IL (1) IL271836A (es)
WO (1) WO2019008144A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2868955T3 (es) 2017-01-17 2021-10-22 Treeway Tw001 B V Tratamiento médico que comprende la administración enteral de edaravona
KR20200024868A (ko) 2017-07-06 2020-03-09 트리웨이 티더블유001 비.브이. 산화성 스트레스-매개 신경퇴행성 질환의 경구 치료에 사용하기 위한 에다라본의 용도
HUE068117T2 (hu) 2018-11-02 2024-12-28 Mitsubishi Tanabe Pharma Corp Edaravon szuszpenzió orális beadáshoz
US20230218577A1 (en) * 2020-06-11 2023-07-13 The Children's Medical Center Corporation Use of heat shock protein inhibitors for the treatment of neurodevelopmental disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE303808T1 (de) 2000-10-24 2005-09-15 Mitsubishi Pharma Corp Mittel zur behandlung der amyotrophischen lateralsklerose (als)
IS7278A (is) 2001-11-26 2003-05-27 Merlyn Associates, Inc. Barkaslanga með stefnustjórnanlegum enda og stöðuhaldandi búnaði
CN1241565C (zh) 2003-04-16 2006-02-15 浙江震元制药有限公司 依达拉奉药物组合物及制备
CN100358520C (zh) * 2003-09-11 2008-01-02 彭建华 具有良好稳定性的注射用依达拉奉粉针剂及其制备方法
CA2555457C (en) * 2004-02-09 2012-08-21 Mitsubishi Pharma Corporation A novel therapeutic agent for amyotrophic lateral sclerosis (als) or diseases caused by als
JP2008001606A (ja) * 2006-06-20 2008-01-10 Mitsubishi Pharma Corp ピラゾロン化合物を含有する水溶液剤
CA2682598C (en) * 2007-04-11 2016-06-07 Biomarin Pharmaceutical Inc. Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
JP2011032220A (ja) * 2009-08-03 2011-02-17 Taiyo Yakuhin Kogyo Kk エダラボン液剤
CN101953832B (zh) 2010-08-10 2012-02-15 南京师范大学 β-环糊精包合依达拉奉的口服药物组合物及其制备方法
CN102349893A (zh) * 2011-08-19 2012-02-15 福建天泉药业股份有限公司 依达拉奉药物组合物
CN107648227A (zh) 2011-09-05 2018-02-02 田边三菱制药株式会社 用于肌萎缩性侧索硬化症的治疗或病情进展抑制的药剂
CN103251554A (zh) 2013-06-06 2013-08-21 南京亿华药业有限公司 一种稳定的依达拉奉注射液及其制备方法
CN105616405B (zh) * 2014-11-05 2021-05-07 中国人民解放军第三军医大学第三附属医院 依达拉奉在制备用于预防和治疗脑淀粉样血管病的药物中的应用
CN113768879A (zh) 2016-03-16 2021-12-10 苏州澳宗生物科技有限公司 依达拉奉剂型
CA3050037A1 (en) 2017-01-17 2018-07-26 Treeway Tw001 B.V. Treatment comprising oral or gastric administration of edaravone
ES2868955T3 (es) 2017-01-17 2021-10-22 Treeway Tw001 B V Tratamiento médico que comprende la administración enteral de edaravona
KR20200024868A (ko) 2017-07-06 2020-03-09 트리웨이 티더블유001 비.브이. 산화성 스트레스-매개 신경퇴행성 질환의 경구 치료에 사용하기 위한 에다라본의 용도

Also Published As

Publication number Publication date
JP2020525458A (ja) 2020-08-27
AU2018298431B2 (en) 2024-03-28
WO2019008144A1 (en) 2019-01-10
IL271836A (en) 2020-02-27
US20200138712A1 (en) 2020-05-07
CN110996944A (zh) 2020-04-10
EP3648760A1 (en) 2020-05-13
US12370139B2 (en) 2025-07-29
BR112020000173A2 (pt) 2020-07-07
EP3648760B1 (en) 2025-11-12
KR20200024868A (ko) 2020-03-09
JP7277005B2 (ja) 2023-05-18
CA3069048A1 (en) 2019-01-10
AU2018298431A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
CL2019003903A1 (es) Uso de edaravona en el tratamiento oral de trastornos neurodegenerativos medidos por estrés oxidativo.
CL2021000382A1 (es) Compuestos novedosos de sulfonamidaurea
CL2019001685A1 (es) Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares.
GEP20227446B (en) New catecholamine prodrugs for use in treatment of parkinson's disease
ZA202001057B (en) Inhibiting ubiquitin specific peptidase 30
CO2019001625A2 (es) Compuestos de captura de aldehído y usos de los mismos
MX2019001575A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
BR112017007975A2 (pt) composições e métodos para o tratamento de disfunção das glândulas meibomianas
CR20190468A (es) Métodos para tratar enfermedades y trastornos mediados por completo
EA201992607A1 (ru) Твердые формы берберина урсодезоксихолата, их композиции и способы
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
CL2020001495A1 (es) Composiciones y método para el tratamiento de enfermedades metabólicas
MX2024002360A (es) Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales.
BR112014013924A2 (pt) métodos para tratar distúrbios cardiovasculares
MX2018003291A (es) Nuevas estrategias terapeuticas contra el cáncer de sangre.
NI201800031A (es) Derivados de oxima de cromona penetrante del cerebro para la terapia de disquinesia inducida por levodopa
BR112017023170A2 (pt) dispositivo de banho medicinal e seu uso
CY1125113T1 (el) Συνθεσεις και μεθοδοι για χρηση στην αγωγη της ομοκυστινουριας
BR112017013674A2 (pt) métodos e composições para tratamento de doenças cerebrais.
CL2019000625A1 (es) Combinación de agonistas de fxr.
CY1124821T1 (el) Ιγμεσινη για χρηση στη θεραπεια της νοσου του αλτσχαιμερ
MX389282B (es) Composiciones y métodos para tratar sinucleinopatías.
MX2021003689A (es) Farmacos precursores de antagonistas del peptido relacionado con el gen para calcitonina (gcrp).
AR114306A1 (es) Tratamiento y prevención de trastornos del sueño
AR109012A1 (es) Sistema de administración transdérmica que contiene galantamina o sales de esta